Clinical Trial Update: Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating two different doses of Revlimid in biochemically relapsed prostate cancer (Phase 1/2) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-04-12